Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions
By
Song, Guo-qiang
He, Tian Li
Ji, Ke-jie
Duan, Yi-meng
Hu, Guo-qiang
April 30, 2026
Clinical Scorecard: Management Strategies for Leptomeningeal Metastasis Following TKI Resistance in EGFR-Mutant Lung Cancer
At a Glance
Category Detail
Condition Leptomeningeal metastasis in EGFR-mutant non-small cell lung cancer Key Mechanisms Resistance to tyrosine kinase inhibitors (TKIs) and limited systemic therapy penetration across the blood-brain barrier Target Population Patients with EGFR-mutant NSCLC experiencing TKI resistance Care Setting Oncology and neurology multidisciplinary care
Key Highlights
Leptomeningeal metastasis presents significant clinical challenges. Current treatment strategies lack standardized protocols. Multimodal treatment approaches can improve neurological prognosis. Emerging immunological strategies are being explored. Logistical challenges and toxicity remain significant obstacles. Guideline-Based Recommendations
Diagnosis
Careful assessment of tumor burden and resistance patterns. Management
Integrate targeted therapies, intrathecal drug administration, and radiotherapy. Monitoring & Follow-up
Regular evaluation of neurological status and treatment response. Risks
Toxicity from combined therapies and unpredictability of efficacy. Patient & Prescribing Data
Patients with EGFR-mutant NSCLC and leptomeningeal metastasis post-TKI resistance.
Personalized treatment regimens are essential due to the heterogeneity of the disease.
Clinical Best Practices
Optimize central nervous system drug delivery. Build collaborative care models among specialists. Related Resources & Content
